Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED) (APEGO)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00687531
First received: May 27, 2008
Last updated: November 3, 2014
Last verified: November 2014

May 27, 2008
November 3, 2014
November 2006
September 2009   (final data collection date for primary outcome measure)
Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
Spirometry was performed to measure FEV1, which is the amount of air the participant is able to exhale in 1 second. Normal values for FEV1 in healthy people depend on age and gender, but values between 80% and 120% of the normal value is considered good. Increased FEV1 indicates improvement in asthma control.
Assess mean change in FEV1 from baseline to the endpoint of the study. [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00687531 on ClinicalTrials.gov Archive Site
  • Morning (AM) and Evening (PM) Peak Expiratory Flow Rate (PEFR) [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
    Participants were to record their daily AM and PM PEFR values in a diary. PEFR can be measured using a peak flow meter that was given to the participant. Normal readings are based on a person's gender, age, and height. A reading of 80 to 100% of the usual or normal peak flow readings indicate that the asthma is under good control. Increased PEFR indicates improvement in asthma control.
  • Number of Items in the Asthma Quality of Life (QOL) Questionnaire and the General QOL Questionnaire That Had a Significant (Positive) Change From Baseline to Endpoint [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]

    Questionnaires consisted of items such as General Health Condition (excellent/very good/good/regular/bad), Difficulty to Breathe (always/almost always/considerable part of time/partially/few amount of time/almost never/never), General Asthma Limitations (completely/a lot/enough to be considered/regular/a few/almost nothing/nothing), etc...

    The questionnaires together consisted of 44 questions, each question with categorical variables as response. A Friedman test was performed to determine the significance of change in samples from baseline to endpoint, for each question.

  • Morning and Evening Asthma Symptoms Based on a 3 Point Scale (4 Individual Symptoms) and 24 Points (Summed). [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
    The symptoms of cough, chest tightness, wheezing, and shortness of breath were each to be graded on a scale of 0 to 3 with 0 being no symptoms present and 3 being very marked symptoms which was disturbing most of the time. Scores were to have been recorded at 12AM and 12PM for a total of 24 points summed.
  • Number of Nocturnal Awakenings [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
  • Number of Puffs of Salbutamol Used Daily [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
  • Investigator's Assessment of Response to Therapy Based on a 5-point Scale [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
    The investigator will assess the subject's response to therapy by interviewing the subject and comparing the current level of symptoms from baseline. A scale of 1 to 5 will be used with 1 being much improved (AM and PM symptom severety/frequency improve >75% from baseline) and 5 being much worse (AM and PM symptom severity/frequency got more than 75% worse from baseline).
  • Patient's Assessment of Response to Therapy Based on a 5-point Scale [ Time Frame: Baseline, Week 12 ] [ Designated as safety issue: No ]
    A scale of 1 to 5 will be used with 1 being much improved (AM and PM symptom severety/frequency improve >75% from baseline) and 5 being much worse (AM and PM symptom severity/frequency got more than 75% worse from baseline).
  • Number of Participants With One or More Mild, Moderate or Severe Asthma Exacerbations [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
    Exacerbation severity will be characterized based on exacerbation classification from the Global Initiative for Asthma (GINA) workshop 2005 and the National Heart Lung and Blood Institute (NHLBI) asthma guidelines.
  • Number of Participants Who Adhered to Treatment [ Time Frame: Day 1 to Week 12 ] [ Designated as safety issue: No ]
    The compliance was measured via medication consumption. In the end of the last week of study (Week 12), a review of the remaining study drug in the initial prescribed Twisthaler device was done. A Twisthaler reading of 0 indicates no study drug left and full compliance.
  • Number of Participants With Use of Rescue Medication in Each Episode [ Time Frame: Day 1 and Week 12 ] [ Designated as safety issue: No ]
  • AM & PM PEFR [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Morning and evening Asthma symptoms based on a 3 point scale (4 individual symptoms) and 24 points (summed). [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Number of Nocturnal Awakenings and use of Rescue Medication in each episode. [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Mean change in Asthma Specific HRQoL Questionnaire and General HRQoL Questionnaire scores from baseline to endpoint [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Number of puffs of salbutamol used daily [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Investigator's assessment of Response to Therapy based on a 5-point scale [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Patient's assessment of Response to Therapy based on a 5-point scale [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Proportion of subjects with one or more mild, moderate or severe asthma exacerbations [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
  • Mean percentage of Treatment Adherence from baseline to endpoint [ Time Frame: Week 12, Visit 5 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)
Open Label, 12-week Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate Dry Powder 400 mcg Once-daily in Persistent Mild-moderate Asthmatic Patients at Least 12 Years Old

Open label, 12-week clinical trial to assess efficacy, safety, treatment adherence and Quality of Life impact of Mometasone Furoate dry powder 400 mcg once-daily in persistent mild-moderate asthmatic patients at least 12 years old.

Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.

Not Provided
Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Asthma
Drug: Mometasone Furoate
Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
Other Name: SCH 32088
Experimental: Mometasone Furoate
Mometasone Furoate 400 mcg once daily in the evening through 12 weeks.
Intervention: Drug: Mometasone Furoate
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
385
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willingness to participate and comply with procedures by signing a written informed consent
  • 12 years of age or older of either gender and any race
  • Women of childbearing potential (includes women who are less than 1 year postmenopausal and currently are or will become sexually active during the study) must be using or agree to use an acceptable method of birth control unless they are surgically sterilized
  • Must understand and be able to adhere to dosing and visit schedules, and agree to record symptom severity scores, PEFR values, medication times, and concomitant medications accurately and consistently in a daily diary.
  • Diagnosed history of mild-moderate persistent asthma for at least 12 months.
  • FEV1 must be >60% of predicted normal or personal best FEV1 during the last 12 months.
  • Using daily inhaled corticosteroids for at least 30 days prior to Screening. In the Screening Visit patients FEV1 should be >= 65% to <= 90% predicted.
  • Asthma Symptom Total daily (AM+PM) severity score at Screening Visit should be <= 2.
  • For two weeks prior to Screening, subjects must have been on a stable regimen of one of the following twice daily regimen: fluticasone propionate (FP) >= 100 - <= 500 mcg/day; budesonide (BUD) >= 200 - <= 1000mcg/day; beclomethasone dipropionate (BDP) >= 200 - <= 1000 mcg/day; triamcinolone acetonide (TA) >= 400 - <= 2000 mcg/day
  • During the inhaled corticosteroid (ICS) Dose Reduction period (max. of 4 weeks; min. of 1 week) of sequential ICS Dose Reduction (approximately 50% reduction in daily dose or discontinue according treatment scheme), subjects must demonstrate a measurable loss of asthma control, with both A) Decreased Lung Function (from the Screening value in absolute FEV1 of >= 10% or >= 220ml OR a decrease in AM PEFR of 25% from the average value for the pre-ICS Dose Reduction period on at least 2 consecutive days out of the last 7 days) AND B) Increased Symptoms (Total AM and PM symptom score of >= 10 out of 24 (using 0-3 scale for each of 4 individual symptoms) on at least 2 days out of the last 7 days OR Increased use of rescue medication from the average value for the pre-ICS Dose Reduction period (one week) of >= 2 puffs on at least 2 days out of the last 7 days)
  • Once criterion above have been fulfilled, subjects can be initiated if the FEV1 is 60%-80% predicted
  • Subjects must agree to inform their usual treating physicians of their participation in this study

Exclusion Criteria:

  • Females who are pregnant or breast-feeding.
  • Subjects who have not observed the designated washout periods for any of the prohibited medications
  • Subjects who have used any investigational product within 30 days or any antibodies for asthma or allergic rhinitis in the past 90 days prior to enrollment.
  • Subjects who have any clinically significant deviation from normal in the physical examination that may interfere with the study evaluations or affect subject safety.
  • Subjects who have required systemic steroids within the previous month.
  • Subjects who are allergic or have an idiosyncratic reaction to corticosteroids.
  • Subjects who have required inpatient hospitalization for asthma control within the previous 3 months, or more than once in the previous 6 months.
  • Subjects with clinical evidence of chronic obstructive pulmonary disease or lung diseases other than asthma.
  • Subjects who have experienced an upper or lower respiratory tract infection within the previous 2 weeks prior to the Screening Visit.
  • Subjects with evidence of clinically significant oropharyngeal candidiasis
  • Subjects with any clinically significant immunologic, metabolic, cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease (other than asthma), or any other disorder which may interfere with the study evaluations or affect subject safety.
  • Subjects with a history of drug abuse, antagonistic personality, poor motivation, hypochondriasis, or any other emotional or intellectual problems that are likely to limit the validity of consent to participate in the study
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00687531
P04879
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
November 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP